ARTICLE | Emerging Company Profile

Epic Bio: Epigenome editing via compact components

Horizons Ventures leads $55M series A for start-up developing compact epigenome editors with all-in-one AAV delivery

July 13, 2022 6:42 PM UTC

Epic Bio is controlling target gene expression using single vectors that combine its highly compact Cas protein with guide RNAs and epigenetic modulators.

“Now that we’ve got the smallest Cas molecule, it opens the door to opportunities,” CEO Amber Salzman told BioCentury. Salzman, a GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) vet, was most recently president and CEO of Ohana Biosciences...